Zafer Soultan

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Zafer Soultan sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials none currently recruiting 1 completed upper half by trial count

Zafer Soultan: 1 sponsored US clinical trial, none currently recruiting.

Zafer Soultan sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. The most-studied condition in this pipeline is Pseudomonas Aeruginosa, with 1 trials.

Mid-pack sponsor footprint

Zafer Soultan is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

1 total, page 1 of 1

COMPLETED

The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

NCT01616862

Therapeutic Areas

Pseudomonas Aeruginosa 1
Cystic Fibrosis 1

How the Zafer Soultan archive is shaped

1 indexed studies, none listed as recruiting (0% open); 1 completed (100%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Pseudomonas Aeruginosa (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Zafer Soultan: archived-pipeline peers nationwide

Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Zafer Soultan sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Zafer Soultan1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Zafer Soultan sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Zafer Soultan sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Zafer Soultan page

1 registered trials is a research-attention snapshot, not an endorsement of Zafer Soultan or any single study.

  • None of Zafer Soultan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Pseudomonas Aeruginosa is the condition Zafer Soultan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pseudomonas Aeruginosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Zafer Soultan pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.